Merck sells API business, drug portfolio in $1B deal

06/28/2013 | Bloomberg · Pharmaceutical Business Review Online

Aspen Group agreed to buy Merck & Co.'s active pharmaceutical ingredient manufacturing business and purchase an option to buy a portfolio of 11 finished dose form molecules that target a range of conditions. The deal is valued at $1 billion. Aspen said the acquisition, which is expected to be finalized this year, will bolster its growth in Latin America, the Asia-Pacific region and other emerging markets.

View Full Article in:

Bloomberg · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park